Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status Prescription; Discontinued
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 38779-0191; 63622-0125; 63622-0123; 65044-7183; 51552-0304; 51927-1726; 45932-0008; 55500-0001; 63622-0124; 62991-1173; 62756-233; 39822-1055; 0469-3051
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cell deathD-dopachrome decarboxylaseP30046Not AvailableNot Available
Cell deathMacrophage migration inhibitory factorP14174T39977Not Available
NeurotoxicityInterleukin-1 alphaP01583T16340Not Available
NeurotoxicityNitric oxide synthase, inducibleQ06518Not AvailableNot Available
NeurotoxicityInterferon gammaP01579T77664Not Available
NeurotoxicityNuclear factor NF-kappa-B p105 subunitP19838T40192Not Available
NeurotoxicityTumor necrosis factorP01375T20178Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Transfusion reaction10.02.04.001; 01.05.01.005; 12.02.08.001--Not Available
Tremor17.01.06.0020.000618%
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.0010.000412%
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Venoocclusive liver disease24.04.07.002; 09.01.06.002--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.008--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000412%
Histiocytosis haematophagic10.02.01.042; 01.05.01.0150.000108%Not Available
Hypoacusis04.02.01.006--
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000108%Not Available
Hyperfibrinogenaemia01.01.02.014--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Infusion related reaction12.02.05.009; 10.01.01.017; 08.01.03.002--
Musculoskeletal discomfort15.03.04.001--Not Available
Type IV hypersensitivity reaction10.01.03.022--Not Available
Nodule08.03.05.002--Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages